Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.56 |
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888345 | 1.00 | SLC17A5 (0.56) | SLC17A5MDM4TP53CASP3TLR2 | |
| SCHEMBL2419146 | 1.00 | SLC17A5 (0.56) | SLC17A5MDM4TP53CASP3TLR2 | |
| SCHEMBL19888241 | 0.90 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3TLR2 | |
| SCHEMBL161752 | 0.87 | MDM4 (0.47) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL161749 | 0.87 | MDM4 (0.47) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL161751 | 0.87 | MDM4 (0.47) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL161750 | 0.87 | MDM4 (0.47) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL14765032 | 0.87 | MDM4 (0.47) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL29386847 | 0.86 | SLC17A5 (0.44) | SLC17A5MDM4TP53CASP3KMT2A | |
| SCHEMBL1486194 | 0.86 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2013036543-A2 | MOLECULAR IMAGING OF CANCER CELLS IN VIVO | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | SLC17A5 445/4885MDM4 481/4885TP53 6/4885 |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | SLC17A5 445/4885MDM4 481/4885TP53 6/4885 |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | SLC17A5 445/4885MDM4 481/4885TP53 6/4885 |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | SLC17A5 445/4885MDM4 481/4885TP53 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.